BioMérieux's molecular cancer diagnosis spinoff has agreed to a $230m purchase by women's health-focused Hologic.
Women’s health technology provider Hologic has agreed to acquire Biotheranostics, a US-based cancer-focused molecular diagnostics technology developer spun off by biotechnology firm BioMérieux, for about $230m.
Founded in 2008, Biotheranostics supplies clinicians with molecular tests to inform cancer diagnoses. Its ests leverage a DNA sample copying-method called polymerase chain reaction to investigate gene expression signatures at high resolution.
The company has two existing products including Breast Cancer Index (BCI), an early-stage breast cancer assay that evaluates the possibility of prescribing…
